Tositumomab: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner

@@ Line 1: / Line 1: @@
 ===Pharmacokinetics===
-{| class="wikitable" border="1" width="52%" style="text-align:center"
+{| class="wikitable" border="1" width="60%" style="text-align:center"
 |-
-!  colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref>
+!  colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref>
 |-
 ! Parameter
@@ Line 10: / Line 10: @@
 ! Ibritumomab
 |-
-! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
 ! Tositumomab
 ! 7.6
@@ Line 16: / Line 16: @@
 ! Ibritumomab
 |-
-! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
 ! Tositumomab
 ! 167000
 ! 205800
-! Ibritumomab
+! 67000
-|-
-! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
-! Tositumomab
-! Ofatumumab
-! Rituximab
-! Ibritumomab
 |-
-! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
+! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
 ! Tositumomab
 ! Ofatumumab
@@ Line 34: / Line 28: @@
 ! Ibritumomab
 |-
-! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
 ! 64.8
 ! 68
 ! 206
-! Ibritumomab
+! 108
 |-
-! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
 ! Tositumomab
 ! 32939000
 ! Rituximab
-! Ibritumomab
+! 17000
 |-
-! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
+! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)
 ! .078
 ! .017
@@ Line 52: / Line 46: @@
 ! Ibritumomab
 |-
-! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
 ! Tositumomab
 ! Ofatumumab